Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapies

Article Page

Abstract

Background: Eribulin mesylate is currently approved in the United States and Europe for the treatment of metastatic breast cancer (MBC).

Scope: The objective of this retrospective study is to find specific predictive criteria related to patient or tumor characteristics in order to select patients that might benefit the most from eribulin and define the correct treatment sequence.

Findings: Forty-four patients with MBC who received eribulin in third or subsequent lines of therapy in a single Italian center were considered eligible. Patients were stratified by body mass index, hormonal/HER2 status, and previous therapies. Primary endpoint was progression free survival (PFS), whereas secondary endpoint was disease control rate (DCR). A longer PFS was found in patients with hormone-positive tumors (p=0.0051), in HER2-negative cases (p=0.037), and in overweight patients (p=0.0015). No difference in efficacy was observed when eribulin was administered in third or subsequent lines of therapy. Significantly longer PFS (p<0.0001) and higher DCR (p=0.035) were achieved by patients previously treated with paclitaxel-bevacizumab in comparison to those pretreated with other drug combinations or with anthracyclines. Prior treatment with nab-paclitaxel seems to have a detrimental effect on PFS (p=0.0008).

Conclusion: Hormone and HER2 status seems a good predictive and prognostic indicator of response to eribulin. Efficacy seems independent from the number of prior therapies, and it is not influenced by prior endocrine treatments and anthracyclines-containing regimens. On the other hand, sensitivity to a prior treatment with paclitaxel-bevacizumab might be predictive of response to eribulin.

Keywords: breast neoplasms, neoplasm metastasis, body mass index, obesity receptors, progesterone, receptors, estrogen, triple negative breast neoplasms, bevacizumab, paclitaxel, taxoids.

Citation: Rossi S, Cassano A, Strippoli A, Schinzari G, D’Argento E, Basso M, Barone C. Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapies. Drugs in Context 2017; 6: 212506. DOI: 10.7573/dic.212506

Contributions: All authors contributed to the collection, analysis, and interpretation of data and participated in the revision and editing of the final manuscript.

Disclosure and potential conflicts of interest: The authors declare to have no conflict of interest. The international Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interest form for the authors is available for download at: http://www.drugsincontext.com/wp-content/uploads/2017/10/dic.212506-COI.pdf

Acknowledgments: Editorial assistance for the preparation of this manuscript was provided by Luca Giacomelli, PhD, and Ambra Corti, on behalf of Content Ed Net. The supporting company was not offered the opportunity to revise the manuscript and had no role in the decision to submit.

Funding declaration: The preparation of this manuscript was funded by Eisai.

Copyright: Copyright © 2017 Rossi S, Cassano A, Strippoli A, Schinzari G, D’Argento E, Basso M, Barone C. Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapies. Distributed under the terms of the Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2017 Rossi S, Cassano A, Strippoli A, Schinzari G, D’Argento E, Basso M, Barone C. https://doi.org/10.7573/dic.212506. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: http://www.drugsincontext.com/prognostic-and-predictive-factors-of-eribulin-efficacy-in-heavily-pretreated-patients-affected-by-metastatic-breast-cancer-correlation-with-tumor-biology-and-previous-therapies

Correspondence: Sabrina Rossi, Humanitas Clinical and Research Center, Via Manzoni, 56, 20089 Rozzano (MI), Italy. sbrn.rossi85@gmail.com

Provenance: submitted; externally peer reviewed.

Submitted: 19 July 2017; Peer review comments to author: 10 August 2017; Revised manuscript received: 26 September 2017; Accepted: 27 September; Publication date: 8 November 2017.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252772009.

For all manuscript and submissions enquiries, contact the Editorial office dic.editorial@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF